Initial Pharmacotherapy for Isolated Depression
Start with a second-generation antidepressant (SSRI or SNRI) as monotherapy, or alternatively cognitive behavioral therapy (CBT) alone—both are equally effective first-line options for moderate to severe depression. 1
Treatment Selection Algorithm
For Moderate to Severe Depression
The 2023 American College of Physicians guideline establishes that monotherapy with either CBT or a second-generation antidepressant should be initiated as first-line treatment 1. Network meta-analyses demonstrate similar benefits between these approaches, though antidepressants carry higher discontinuation rates due to adverse events 2.
Specific medication selection should be guided by predominant symptoms:
- For anxiety symptoms: Start escitalopram or sertraline 3
- For loss of interest/motivation: Start duloxetine or venlafaxine 3
- For insomnia, loss of appetite, or suicidal ideation: Start mirtazapine 3
For Mild Depression
Start with CBT monotherapy rather than antidepressants 1. The guideline makes a conditional recommendation for psychotherapy alone in mild cases, as the benefit-to-harm ratio favors non-pharmacologic intervention when symptom severity is lower.
Combination Therapy Consideration
Combination therapy (CBT plus antidepressant) can be considered for moderate to severe depression, though this is a conditional recommendation based on low-certainty evidence 1. The 2024 update alert reinforces that combination approaches show higher remission rates (57.5-78.7%) compared to antidepressant monotherapy (31.0-45.2%) 4.
Critical Caveats
- Over 60% of patients experience at least one adverse effect from second-generation antidepressants 2
- Up to 70% do not achieve remission with initial treatment, necessitating second-step strategies 2
- The certainty of evidence is low to moderate for most comparisons, meaning treatment decisions must weigh adverse effect profiles, cost, and patient preferences 2, 1
- All second-generation antidepressants demonstrate comparable efficacy—the choice hinges on side effect profile matching patient symptoms and tolerability concerns 5
Practical Implementation
When prescribing antidepressants, ensure adequate dosing and duration (at least 6 weeks) before declaring treatment failure 2. The evidence does not support one specific SSRI or SNRI over another for general depression without specific symptom targets 5.